Strategic collaborations Smart Immune is actively pursuing collaborations with leading institutions in the US and Europe, presenting opportunities to partner on clinical studies, co-development, or sponsored research to accelerate ProTcell adoption in hematology and immune-oncology.

Clinical-stage momentum With SMART101 in Phase I/II for AML, ALL, and SCID trials, there is a clear path to expanded trials and later-stage partnerships, offering potential licensing, supply agreements, and joint ventures as therapies progress.

Strong funding signals Recent $5 million Gates Foundation investment and €17.5 million in EU funding underscore investor confidence and financial runway, creating openings for tiered collaborations, grants-driven programs, and funded development partnerships.

Off-the-shelf potential ProTcell platform enables gene-modified T cell progenitors and off-the-shelf CAR T approaches, suggesting sales opportunities in manufacturing services, GMP-ready supply, and technology licensing for scalable allogeneic therapies.

Global expansion readiness Headquartered in Paris with multinational trial activity and a diverse tech stack, Smart Immune is well-positioned to engage global CROs, clinical supply chains, and regional partners to accelerate market access and clinical outcomes.